Cite
HARVARD Citation
Lawitz, E. et al. (2020). Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. Lancet gastroenterology and hepatology. pp. 918-926. [Online].